Cell cycle arrest and DNA damage after melphalan treatment of the human myeloma cell line RPMI 8226

2009 ◽  
Vol 47 (3) ◽  
pp. 161-167 ◽  
Author(s):  
Jan-Olof Fernberg ◽  
Rolf Lewensohn ◽  
Sven Skog
Life Sciences ◽  
2013 ◽  
Vol 92 (1) ◽  
pp. 55-62 ◽  
Author(s):  
Meng Zhang ◽  
Li-Ping Liu ◽  
Yuling Chen ◽  
Xiao-ying Tian ◽  
Jian Qin ◽  
...  

Blood ◽  
1998 ◽  
Vol 91 (7) ◽  
pp. 2423-2432 ◽  
Author(s):  
Bertrand Joseph ◽  
Olga Lefebvre ◽  
Claude Méreau-Richard ◽  
Pierre-Marie Danzé ◽  
Marie-Thérèse Belin-Plancot ◽  
...  

In this study, we show that both all-trans-retinoic acid (atRA) and 9-cis-retinoic acid (9-cis-RA) are potent inducers of tissue transglutaminase (TGase II), an enzyme involved in apoptosis, at the level of both enzyme activity and mRNA in the human myeloma cell line RPMI 8226. RPMI 8226 cells were shown to express mRNAs for all the retinoid receptors subtypes, ie, RARα, RARβ, RARγ, RXRα, RXRβ, and RXRγ. To identify which of these receptors are involved in regulating TGase II expression, several receptor-selective synthetic retinoids were used. Neither CD367, a very potent retinoid that selectively binds and activates receptors of the RAR family, nor CD2425, an RXR-selective agonist, induced TGase II when used alone. However, combination of CD367 and CD2425 resulted in nearly full induction of the enzyme. Moreover, when used in combination with atRA, CD367 partially inhibited the atRA-dependent induction of TGase II, whereas CD2425 enhanced it. The effects of Am 580, CD417, and CD437, three synthetic retinoids selective for the RARs subtypes RARα, RARβ, and RARγ, respectively, were also investigated. None of these compounds was able to induce TGase II when used alone; however, the combination of each of them with CD2425 resulted in strong induction of the enzyme activity, reaching 30% to 50% of the values obtained in the presence of retinoic acid and suggesting functional redundancy between the RAR subtypes. Finally, treatment with atRA or the combination of CD367 and CD2425, but not with CD367 or CD2425 alone, was also shown to trigger apoptosis in RPMI 8226 cells, with prominent accumulation of TGase II immunoreactivity in apoptotic cells. Taken together these data suggest that the induction of TGase II expression and apoptosis in the RPMI 8226 myeloma cell line required ligand-dependent activation of both the RAR and RXR receptors.


Blood ◽  
1998 ◽  
Vol 91 (7) ◽  
pp. 2423-2432 ◽  
Author(s):  
Bertrand Joseph ◽  
Olga Lefebvre ◽  
Claude Méreau-Richard ◽  
Pierre-Marie Danzé ◽  
Marie-Thérèse Belin-Plancot ◽  
...  

AbstractIn this study, we show that both all-trans-retinoic acid (atRA) and 9-cis-retinoic acid (9-cis-RA) are potent inducers of tissue transglutaminase (TGase II), an enzyme involved in apoptosis, at the level of both enzyme activity and mRNA in the human myeloma cell line RPMI 8226. RPMI 8226 cells were shown to express mRNAs for all the retinoid receptors subtypes, ie, RARα, RARβ, RARγ, RXRα, RXRβ, and RXRγ. To identify which of these receptors are involved in regulating TGase II expression, several receptor-selective synthetic retinoids were used. Neither CD367, a very potent retinoid that selectively binds and activates receptors of the RAR family, nor CD2425, an RXR-selective agonist, induced TGase II when used alone. However, combination of CD367 and CD2425 resulted in nearly full induction of the enzyme. Moreover, when used in combination with atRA, CD367 partially inhibited the atRA-dependent induction of TGase II, whereas CD2425 enhanced it. The effects of Am 580, CD417, and CD437, three synthetic retinoids selective for the RARs subtypes RARα, RARβ, and RARγ, respectively, were also investigated. None of these compounds was able to induce TGase II when used alone; however, the combination of each of them with CD2425 resulted in strong induction of the enzyme activity, reaching 30% to 50% of the values obtained in the presence of retinoic acid and suggesting functional redundancy between the RAR subtypes. Finally, treatment with atRA or the combination of CD367 and CD2425, but not with CD367 or CD2425 alone, was also shown to trigger apoptosis in RPMI 8226 cells, with prominent accumulation of TGase II immunoreactivity in apoptotic cells. Taken together these data suggest that the induction of TGase II expression and apoptosis in the RPMI 8226 myeloma cell line required ligand-dependent activation of both the RAR and RXR receptors.


1988 ◽  
Vol 57 (3) ◽  
pp. 290-292 ◽  
Author(s):  
BC Millar ◽  
JL Millar ◽  
A Jones ◽  
SW Feary ◽  
D Robertson ◽  
...  

2016 ◽  
Vol 76 (1) ◽  
pp. 59-65 ◽  
Author(s):  
P. J. J. Trojan ◽  
M. S. Bohatch-Junior ◽  
M. F. Otuki ◽  
F. Souza-Fonseca-Guimarães ◽  
P. V. Svidnicki ◽  
...  

Abstract Multiple myeloma (MM) is a B cell bone marrow neoplasia characterized by inflammation with an intense secretion of growth factors that promote tumor growth, cell survival, migration and invasion. The aim of this study was to evaluate the effects of pravastatin, a drug used to reduce cholesterol, in a MM cell line.Cell cycle and viability were determinate by Trypan Blue and Propidium Iodide. IL6, VEGF, bFGF and TGFβ were quantified by ELISA and qRT-PCR including here de HMG CoA reductase. It was observed reduction of cell viability, increase of cells in G0/G1 phase of the cell cycle and reducing the factors VEGF and bFGF without influence on 3-Methyl-Glutaryl Coenzyme A reductase expression.The results demonstrated that pravastatin induces cell cycle arrest in G0/G1 and decreased production of growth factors in Multiple Myeloma cell line.


PLoS ONE ◽  
2017 ◽  
Vol 12 (8) ◽  
pp. e0182152 ◽  
Author(s):  
Etsuko Tokunaga ◽  
Hidehiko Akiyama ◽  
Vadim A. Soloshonok ◽  
Yuki Inoue ◽  
Hideaki Hara ◽  
...  

Science ◽  
1982 ◽  
Vol 216 (4549) ◽  
pp. 997-999 ◽  
Author(s):  
A Karpas ◽  
P Fischer ◽  
D Swirsky

Sign in / Sign up

Export Citation Format

Share Document